HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2006.069237v1 63/1/53    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tillie-Leblond, I Articles by Cadranel, J Search for Related Content PubMed PubMed Citation Articles by Tillie-Leblond, I Articles by Cadranel, J

Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset

¹ Service de Pneumologie et Réanimation Respiratoire, Hôpital Tenon, Paris, France
² Service de Pneumologie, Hôpital Avicenne, Bobigny, France
³ Service de Pneumologie, Hôpital Bichat, Paris, France
⁴ Service de Pneumologie, Hotel-Dieu, Paris, France
⁵ Service de Pneumologie, Hôpital Européen G Pompidou, Paris, France
⁶ Service de Pneumologie, Hôpital Béclère, Clamart, France
⁷ Service de Pneumologie, Hôpital Foch, Suresnes, France
⁸ Service de Pneumologie, Hôpital Calmette, Lille, France

Correspondence to:
Dr J Cadranel, Service de Pneumologie et Réanimation Respiratoire, Hôpital Tenon, 4 rue de la Chine, 75970 Paris Cedex 20, France; jacques.cadranel{at}tnn.aphp.fr

Aim: A multicentre retrospective study was undertaken to examine patients with interstitial lung disease (ILD) with the initial clinical manifestation of an anti-synthetase syndrome (anti-Jo-1 antibodies), and to analyse the characteristics and long-term outcome of these patients according to their clinical presentation (acute or gradual onset), treatment and adverse events related to treatment.

Methods: 32 patients, 15 (47%) presenting with acute onset and associated respiratory insufficiency (group A) and 17 (53%) with gradual onset (group G) were examined. Myositis was diagnosed at admission in only 31% of cases and was observed during follow-up in 56% of cases, but the prevalence did not differ between the two groups.

Results: Fever and radiological patterns including diffuse patchy ground-glass opacities, basal irregular lines and consolidation on high-resolution CT scan were more frequent in group A than in group G. More patients in group G had neutrophils in the bronchoalveolar lavage fluid and autoantibodies other than anti-Jo-1 (rheumatoid factor, anti SSa/SSb) than in group A. The percentage of patients in whom the ILD improved at 3 months was significantly higher in group A than in group G (13/15 vs 9/17; p = 0.006). In contrast, after 12 months, most patients with ILD progression were in group A and were treated with corticosteroids alone. A combination of corticosteroids and an immunosuppressive drug was required in most cases (84%) at the end of the follow-up period. Severe adverse effects of treatment were observed and varicella zoster virus infection was frequent.

Conclusions: Early testing for anti-synthetase antibodies, particularly anti-Jo-1, and creatine kinase determination are useful procedures in patients presenting with ILD. Treatment with corticosteroids and immunosuppressive drugs is required in most patients. At the end of the study, around two-thirds of patients had stable ILD while the other third had disease progression with respiratory insufficiency.

This article has been cited by other articles:

				R. Polosa and C. J. Edwards Tacrolimus for antisynthetase syndrome with interstitial lung disease? Eur. Respir. J., July 1, 2008; 32(1): 244 - 245. [Full Text] [PDF]

				L. P. Nicod From the authors Eur. Respir. J., July 1, 2008; 32(1): 245 - 246. [Full Text] [PDF]